Meditip

About Meditip

Meditip is a healthcare consulting firm specializing in guiding bio-ventures and medical device companies through the complexities of global market entry. Founded in April 2007 by Yoo Jeong-hee, the company provides comprehensive support for the successful development and commercialization of biopharmaceuticals, medical devices, and health functional foods. In April 2025, Park Yang-soo, a regulatory affairs (RA) strategy expert with approximately 25 years of experience, was appointed as the new CEO to enhance the company's expertise in preparation for a potential IPO.

The company's business model is centered on providing a suite of specialized consulting services on a B2B basis. Its core offerings include navigating the regulatory and licensing processes in key global markets such as Korea, the U.S. (FDA), Europe (EMA), China (NMPA), and Japan (PMDA). Meditip achieves this through its internal expertise and a network of global partners, including Tigermed. The firm's services cover the entire product lifecycle, from R&D support and clinical trial development to product licensure, reimbursement strategies, and post-market surveillance. Additionally, Meditip offers CDMO (Contract Development and Manufacturing Organization) operations consulting to help clients manage the production of investigational new drugs and secure necessary documentation.

For foreign companies seeking to enter the Korean market without establishing a local entity, Meditip acts as an In-Country Caretaker (ICC). In this capacity, it serves as a legal representative, managing everything from initial product registration and GMP compliance to overseeing sales, distribution, and logistics partners. This one-stop service simplifies market access and ensures stable product supply and compliance with local regulations. In March 2022, Meditip was acquired by Dream CIS, a clinical research organization (CRO), creating a platform that offers a total service encompassing regulatory affairs, clinical trials, and global expansion.